Treatment of Treatment-Naive CLL Without TP53 Mutation or 17p Deletion

This protocol applies to patients with chronic lymphocytic leukaemia who have not previously received treatment, meet established iwCLL criteria for initiating therapy, and whose disease is confirmed to carry neither a TP53 mutation nor a 17p chromosomal deletion.

Clinical Scenario

Treatment-naive CLL meeting iwCLL treatment criteria
No TP53 mutation detected
No 17p deletion

The absence of TP53 disruption is a key determinant of regimen selection at first-line, informing the range of treatment strategies that can be considered for this population.

Treatment Approach

First-line targeted therapy is the approach for this population. Both fixed-duration and continuous treatment strategies are available, and no single regimen carries a universal recommendation over the others — the choice depends on patient-specific factors addressed in the full protocol.

The complete regimen options, clinical considerations, and selection guidance are available in the full protocol below.

Instant Access to Structured Evidence-Based Regimens

References

First line treatment for patients without TP53 disruption.

Since publication of the 2022 guideline, the fixed-duration 15-month venetoclax-ibrutinib (V+I) and the fixed duration venetoclax-acalabrutinib+/−obinutuzumab (V+A+/−O) regimens have been licensed, and data on the venetoclax–obinutuzumab (V+O) regimen across all age ranges have been updated.

If a fixed-duration regimen is chosen, no specific recommendation can be given between V+O or V+I.

Acalabrutinib–obinutuzumab (A+O, MHRA [no NICE TA/SMC], FDA, EMA) is a first-line treatment option for all patients without TP53 disruption and has higher efficacy but increased toxicity compared to acalabrutinib monotherapy (GRADE 1B).

View source ↗